CVR - Coronavirus Vaccines R&D Roadmap

Milestone
2.3.d

T-cell epitopes

In progress

Identify T-cell epitopes that elicit CD4 and CD8 responses, offering broad cross-protection against different coronaviruses, and how this response is impacted by HLA diversity.

Progress Highlights

Wang 2024 identified 3 N-protein CD8+ T-cell epitopes that were conserved between SARS-CoV and SARS-CoV-2:

  • Epitope N262-270: Conserved between SARS-CoV-2 and SARS-CoV with a single substitution (K→Q at position 266).
    • Retains structural similarity, allowing cross-reactivity
  • Epitope N266-274: Conserved between SARS-CoV-2 and SARS-CoV with a single substitution (A→Q at position 267).
    • High conservation of binding regions
    • Shown to be presented by multiple HLA alleles, enabling broader population coverage.
  • Epitope N261-277: Minor variations between SARS-CoV and SARS-CoV-2 forms
    • Retained cross-reactivity
    • Stimulates both CD4+ and CD8+ T cells.
    • Recognized across diverse HLA types

Meyer 2023 identified 7 non-spike CD8+ T-cell epitopes conserved across all SARS-CoV-2 variants of concern tested.

  • N262-270, N266-274, N261-277
  • M105-113
  • ORF3a(206-215), ORF3a*203-212), ORF3a(139-147)

Meyer 2023 identified 7 non-spike CD8+ T-cell epitopes conserved across all SARS-CoV-2 variants of concern tested.

  • N262-270, N266-274, N261-277
  • M105-113
  • ORF3a(206-215), ORF3a*203-212), ORF3a(139-147)

Meyer 2023 identified 7 non-spike CD8+ T-cell epitopes conserved across all SARS-CoV-2 variants of concern tested.

  • N262-270, N266-274, N261-277
  • M105-113
  • ORF3a(206-215), ORF3a*203-212), ORF3a(139-147)